Length of Barrett's oesophagus and cancer risk: Implications from a large sample of patients with early oesophageal adenocarcinoma

Gut

Volumn 65, Issue 2, 2016, Pages 196-201

  Pohl, Heiko ^a,b   Pech, Oliver ^c   Arash, Haris ^d   Stolte, Manfred ^e   Manner, Hendrik ^d   May, Andrea ^d,f   Kraywinkel, Klaus ^g   Sonnenberg, Amnon ^h   Ell, Christian ^d,f  

^a VA MEDICAL CENTER   (United States)

^b DARTMOUTH HITCHCOCK MEDICAL CENTER   (United States)

^c St Hedwig Clinic   (Germany)

^d HSK Wiesbaden ^*  (Germany)

^e Klinikum Kulmbach   (Germany)

^f SANA KLINIKUM OFFENBACH   (Germany)

^g ROBERT KOCH INSTITUTE   (Germany)

^h PORTLAND VA MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AGED; ARTICLE; BARRETT ESOPHAGUS; CANCER DIAGNOSIS; CANCER INCIDENCE; CANCER RISK; DISEASE ASSOCIATION; DISEASE SEVERITY; ENDOSCOPY; ESOPHAGEAL ADENOCARCINOMA; FEMALE; GERMANIC PEOPLE; HUMAN; INCIDENCE; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; ADENOCARCINOMA; CELL TRANSFORMATION; ESOPHAGEAL NEOPLASMS; ESOPHAGUS; GERMANY; MIDDLE AGED; PATHOLOGY; PREVALENCE; SENSITIVITY AND SPECIFICITY; UNITED STATES;

ADENOCARCINOMA; AGED; BARRETT ESOPHAGUS; CELL TRANSFORMATION, NEOPLASTIC; ESOPHAGEAL NEOPLASMS; ESOPHAGUS; FEMALE; GERMANY; HUMANS; MALE; MIDDLE AGED; PREVALENCE; SENSITIVITY AND SPECIFICITY; UNITED STATES;

EID: 84958853462     PISSN: 00175749     EISSN: 14683288     Source Type: Journal    
DOI: 10.1136/gutjnl-2015-309220     Document Type: Article

References (40)

1. Pohl H, Sirovich B, Welch HG. Esophageal adenocarcinoma incidence: are we reaching the peak? Cancer Epidemiol Biomarkers Prev 2010;19:1468-70.
2. Committee ASoP Evans JA, Early DS, Fukami N, et al. The role of endoscopy in Barrett's esophagus and other premalignant conditions of the esophagus. Gastrointest Endosc 2012;76:1087-94.
3. Spechler SJ, Sharma P, Souza RF, et al. American Gastroenterological Association medical position statement on the management of Barrett's esophagus. Gastroenterology 2011;140:1084-91.
4. Ell C, May A, Gossner L, et al. Endoscopic mucosal resection of early cancer and high-grade dysplasia in Barrett's esophagus. Gastroenterology 2000;118:670-7.
5. Pech O, May A, Manner H, et al. Long-term efficacy and safety of endoscopic resection for patients with mucosal adenocarcinoma of the esophagus. Gastroenterology 2014;146:652-660.e1.
6. Coleman HG, Bhat SK, Murray LJ, et al. Symptoms and endoscopic features at Barrett's esophagus diagnosis: implications for neoplastic progression risk. Am J Gastroenterol 2014;109:527-34.
7. Avidan B, Sonnenberg A, Schnell TG, et al. Hiatal hernia size, Barrett's length, and severity of acid reflux are all risk factors for esophageal adenocarcinoma. Am J Gastroenterol 2002;97:1930-6.
8. Pohl H, Wrobel K, Bojarski C, et al. Risk factors in the development of esophageal adenocarcinoma. Am J Gastroenterol 2013;108:200-7.
9. Weston AP, Badr AS, Hassanein RS. Prospective multivariate analysis of clinical, endoscopic, and histological factors predictive of the development of Barrett's multifocal high-grade dysplasia or adenocarcinoma. Am J Gastroenterol 1999;94:3413-19.
10. Wani S, Falk G, Hall M, et al. Patients with nondysplastic Barrett's esophagus have low risks for developing dysplasia or esophageal adenocarcinoma. Clin Gastroenterol Hepatol 2011;9:220-7; quiz e26.
11. Menke-Pluymers MB, Hop WC, Dees J, et al. Risk factors for the development of an adenocarcinoma in columnar-lined (Barrett) esophagus. The Rotterdam Esophageal Tumor Study Group. Cancer 1993;72:1155-8.
12. Desai TK, Krishnan K, Samala N, et al. The incidence of oesophageal adenocarcinoma in non-dysplastic Barrett's oesophagus: a meta-analysis. Gut 2012;61:970-6.
13. Fitzgerald RC, di Pietro M, Ragunath K, et al. British Society of Gastroenterology guidelines on the diagnosis and management of Barrett's oesophagus. Gut 2014;63:7-42.
14. Koop H, Fuchs KH, Labenz J, et al. [S2k guideline: gastroesophageal reflux disease guided by the german society of gastroenterology]. Z Gastroenterol 2014;52:1299-346.
15. Kraywinkel K, Barnes B, Dahm S, et al. [Nationwide statements from regional data: methods of the Center for Cancer Registry Data]. Bundesgesundheitsblatt Gesundheitsforschung Gesundheitsschutz 2014;57:13-21.
16. Haberland J, Bertz J, Wolf U, et al. German cancer statistics 2004. BMC Cancer 2010;10:52.
17. German Cancer For Cancer Registry Data. 2015. http://www.krebsdaten.de/Krebs/EN/Home/homepage-node.html
18. Ronkainen J, Aro P, Storskrubb T, et al. Prevalence of Barrett's esophagus in the general population: an endoscopic study. Gastroenterology 2005;129:1825-31.
19. Zagari RM, Fuccio L, Wallander MA, et al. Gastro-oesophageal reflux symptoms, oesophagitis and Barrett's oesophagus in the general population: the Loiano-Monghidoro study. Gut 2008;57:1354-9.
20. Hirota WK, Loughney TM, Lazas DJ, et al. Specialized intestinal metaplasia, dysplasia, and cancer of the esophagus and esophagogastric junction: prevalence and clinical data. Gastroenterology 1999;116:277-85.
21. Meining A, Ott R, Becker I, et al. The Munich Barrett follow up study: suspicion of Barrett's oesophagus based on either endoscopy or histology only - what is the clinical significance? Gut 2004;53:1402-7.
22. Gerson LB, Shetler K, Triadafilopoulos G. Prevalence of Barrett's esophagus in asymptomatic individuals. Gastroenterology 2002;123:461-7.
23. Rex DK, Cummings OW, Shaw M, et al. Screening for Barrett's esophagus in colonoscopy patients with and without heartburn. Gastroenterology 2003;125:1670-7.
24. Ward EM, Wolfsen HC, Achem SR, et al. Barrett's esophagus is common in older men and women undergoing screening colonoscopy regardless of reflux symptoms. Am J Gastroenterol 2006;101:12-17.
25. Spechler SJ, Zeroogian JM, Antonioli DA, et al. Prevalence of metaplasia at the gastro-oesophageal junction. Lancet 1994;344:1533-6.
26. Wallner B, Sylvan A, Stenling R, et al. The esophageal Z-line appearance correlates to the prevalence of intestinal metaplasia. Scand J Gastroenterol 2000;35:17-22.
27. Dickman R, Levi Z, Vilkin A, et al. Predictors of specialized intestinal metaplasia in patients with an incidental irregular Z line. Eur J Gastroenterol Hepatol 2010;22:135-8.
28. de Jonge PJ, van Blankenstein M, Grady WM, et al. Barrett's oesophagus: epidemiology, cancer risk and implications for management. Gut 2014;63:191-202.
29. Dekel R, Wakelin DE, Wendel C, et al. Progression or regression of Barrett's esophagus - is it all in the eye of the beholder? Am J Gastroenterol 2003;98:2612-15.
30. Cameron AJ, Lomboy CT. Barrett's esophagus: age, prevalence, and extent of columnar epithelium. Gastroenterology 1992;103:1241-5.
31. Hvid-Jensen F, Pedersen L, Drewes AM, et al. Incidence of adenocarcinoma among patients with Barrett's esophagus. N Engl J Med 2011;365:1375-83.
32. Bhat S, Coleman HG, Yousef F, et al. Risk of malignant progression in Barrett's esophagus patients: results from a large population-based study. J Natl Cancer Inst 2011;103:1049-57.
33. de Jonge PJ, van Blankenstein M, Looman CW, et al. Risk of malignant progression in patients with Barrett's oesophagus: a Dutch nationwide cohort study. Gut 2010;59:1030-6.
34. Kroep S, Lansdorp-Vogelaar I, Rubenstein JH, et al. Comparing trends in esophageal adenocarcinoma incidence and lifestyle factors between the United States, Spain, and the Netherlands. Am J Gastroenterol 2014;109:336-43; quiz 335, 344.
35. Castro C, Bosetti C, Malvezzi M, et al. Patterns and trends in esophageal cancer mortality and incidence in Europe (1980-2011) and predictions to 2015. Ann Oncol 2014;25:283-90.
36. Thrift AP, Whiteman DC. The incidence of esophageal adenocarcinoma continues to rise: analysis of period and birth cohort effects on recent trends. Ann Oncol 2012;23:3155-62.
37. Liu W, Hahn H, Odze RD, et al. Metaplastic esophageal columnar epithelium without goblet cells shows DNA content abnormalities similar to goblet cell-containing epithelium. Am J Gastroenterol 2009;104:816-24.
38. Westerhoff M, Hovan L, Lee C, et al. Effects of dropping the requirement for goblet cells from the diagnosis of Barrett's esophagus. Clin Gastroenterol Hepatol 2012;10:1232-6.
39. Vakil N, van Zanten SV, Kahrilas P, et al. The Montreal definition and classification of gastroesophageal reflux disease: a global evidence-based consensus. Am J Gastroenterol 2006;101:1900-20; quiz 1943.
40. Lieberman DA, Rex DK, Winawer SJ, et al. Guidelines for colonoscopy surveillance after screening and polypectomy: a consensus update by the US multi-society task force on colorectal cancer. Gastroenterology 2012;143:844-57.